Navigation Links
Global Cryptococcosis Market to Reach US$6.2 Billion by 2024: Link to Growing HIV Cases Raising Treatment Availability Concerns, Observes TMR

ALBANY, New York, February 1, 2017 /PRNewswire/ --

The highly fragmented Global Cryptococcosis Market is being pioneered by only a handful of players based in developed regions of the world. Pfizer, Inc., Valeant Pharmaceuticals, Inc., Bristol-Myers Squibb Company, and Janssen Biotech, Inc. had collectively held a share of 41% in the global cryptococcosis market in terms of value, for 2015. Their dominance in the market was marked by factors such as operating stronghold in developed economies where the demand and awareness are high, better brand name recognition, and higher investments in research and development.

Transparency Market Research reveals in a recently released market intelligence report that leading players from the global cryptococcosis market are likely to participate in a wave of mergers and acquisitions in all key regions of the market over the coming years. Business conglomerates have significant investments in the recent past to bring to fruition their research and development efforts for new drugs and are interested in expanding their distribution chain to broader regions. The global cryptococcosis market was calculated to reach US$4.31 bn by the end of 2016, and is projected to reach US$6.2 bn by the end of 2024, after expanding at a CAGR of 4.8% from 2016 to 2024.

Download PDF Brochure of Research Report:

Cryptococcosis Count Rising across the Globe 

"The key factor currently working for the growth of the global cryptococcosis market is the growing count of patients being infected by the disease. Although previously classified as a rarely occurring illness, cryptococcosis is seen to be growing in count across the globe and the healthcare industry is aware of this. The CDC had stated earlier that close to a million new cases of cryptococcosis are being spotted globally each year and are the cause of 625,000 deaths. The current gold standard for cryptococcosis treatment - Amphotericin B plus oral flucytosin - is at the forefront of the demand so far. The scope for other existing and pipeline treatments is also very high," states a TMR analyst.

Aiding the growth rate of the global cryptococcosis market are multiple governments highly interested in eradicating the disease from their nations. The increasingly powerful efforts put in by governments are allowing players in the market to invest better into advanced treatment options and the development on pipeline drugs, as well as the better distribution of existing ones. The count of cryptococcosis patients is also directly linked to the diagnosis of HIV, which is another growing count in the world. The increasing number of HIV patients are shown to be highly likely to develop cryptococcosis during late-stage HIV infection, further pushing the demand for cryptococcosis treatment.

High Cryptococcosis Mortality Rate Hampers R&D 

One of the key factors holding the global cryptococcosis market back currently is the very high mortality rate among cryptococcosis patients. Pneumocystis pneumonia and cryptococcal meningitis are the two greater fungal infections that lead to death in the world. The mortality rate of HIV patients who get diagnosed with cryptococcosis is extremely close to 100%. This gives a very minor scope of development of existing and pipeline drugs as it can cripple the overall testing phase. The market is also expected to face severe degradation of quality due to the imminent patent expirations and the consequent surge of generics. Their extremely low pricing will allow them to take up large demand volumes in all regions, disallowing branded manufacturers from generating enough to invest in further research and development.

"The future of the global cryptococcosis market can lie in the installation of integrated facilities in the regions where penetration potential is currently at an all-time high. These integrated facilities can allow manufacturers in the pharmaceutical industry to reduce operating costs and increase production speeds, allowing them to maintain a competitive edge against rivals," adds the analyst.

Inquire for Report Customization:

The information presented in this review is based on a Transparency Market Research report, titled, "Cryptococcosis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024."

Key segments of the Global Cryptococcosis Market 

Global Cryptococcosis Market, by Treatment, 

  • Amphotericin B
    • Amphocin
    • Fungizone
    • Other
  • Flucytosine
    • Ancobon
    • Other
  • Fluconazole
    • Diflucan
    • Other
  • Others (Voriconazole, surgery treatment, etc.)

Global Cryptococcosis Market, by Distribution Channel 

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • Mail Order Pharmacies
  • Other

Global Cryptococcosis market, by Region 

  • North America
    • U.S.
    • Canada
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America

Browse Related Research Report: 

Pharmaceutical Products and CMO Market: (Product Type - API and Ingredients, Finished Dosage Form, and Pharmaceutical Packaging) - LATAM Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Testing and Analysis Services Market: (By Sample Type: Water, Soil/Sediment, Clay Mineral, Metal Alloy, Biological Sample, Food, Chemicals, Corrosion, Oil and Gas, and Minerals and Ores; By Analysis Type: Elemental, Organic, Isotopic, Particle Size, Mineralogical, Metallurgical, Petroleum and Petrochemical, Biomedical and Biopharmaceutical, and Others; By Industry: Food/Beverages, Pharma/Medical Device, Energy, Minerals, Chemicals and Other Commodities, Environment and Metal and Alloy - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

About Us: 

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact Us:
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453


SOURCE Transparency Market Research
Copyright©2017 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
4. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. TRACE Releases 2012 Global Enforcement Report
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
(Date:12/4/2019)... ... December 04, 2019 , ... Intalere, ... and clinical health for our partners, today announced Steve Kiewiet, Intalere Chief ... Healthcare Executives (ACHE). , ACHE is an international professional society of 48,000 ...
(Date:12/2/2019)... ... December 02, 2019 , ... Smile ... dental groups in the United States, today announced the grand opening of another ... , Patients will enjoy convenient hours, a comfortable office and full-service care ...
(Date:11/30/2019)... ... November 29, 2019 , ... Transpara™ 1.6, the leading ... algorithms to automatically detect potential breast cancer in 2D and 3D DBT mammograms, ... meeting, December 1-6, 2019 (ScreenPoint Medical, South Hall #4380). , The software uniquely ...
Breaking Medicine Technology:
(Date:12/9/2019)... (PRWEB) , ... December 09, 2019 , ... ... device companies, today announced new updates to the platform’s - - Change ... customers’ ability to identify, assess, and track the items impacted by change orders ...
(Date:12/9/2019)... ... 2019 , ... OCLI, a Spectrum Vision Partners (SVP) managed practice, has announced ... and Ophthalmology practice with experience spanning decades. As part of OCLI, Drs. Cary Silverman, ... location at 46 Eagle Rock Ave, East Hanover, NJ 07936. , Over ...
(Date:12/8/2019)... ... December 07, 2019 , ... More than 85 million people across the ... the American Academy of Dermatology, indicating this problem is more common than previously believed. ... years to come. These dermatological conditions vary in type and severity and span all ...
(Date:12/8/2019)... ... December 08, 2019 , ... ... has announced the Top 26 Logistics Degree Programs for 2020. The comprehensive research ... the nation. Each program is evaluated based on curriculum quality, graduation rate, reputation, ...
(Date:12/6/2019)... ... 2019 , ... C&A Industries , a national leader ... Omaha-based company has been named by Training magazine to the Training Top ... programs worldwide. Rankings of the 125 leading companies will be announced on Feb. ...
Breaking Medicine News(10 mins):